GGrantIndex
← Search

Biomolecular Resource Laboratory

$188,707P30FY2009CANIH

Wake Forest University Health Sciences, Winston-Salem NC

Investigators

Linked publications, trials & patents

Trial NCT07614022Trial NCT07324577Trial NCT07322367Trial NCT07282444Trial NCT07203534Trial NCT07196241Trial NCT07175376Trial NCT07119489Trial NCT07046936Trial NCT06945042Trial NCT06709404Trial NCT06654245Trial NCT06480591Trial NCT06441266Trial NCT06340503Trial NCT05984680Trial NCT05934851Trial NCT05877404Trial NCT05854966Trial NCT05825066Trial NCT05796518Trial NCT05696782Trial NCT05692635Trial NCT05597878Trial NCT05395936Trial NCT05309655Trial NCT05242770Trial NCT05212272Trial NCT05204290Trial NCT05030038Trial NCT04897217Trial NCT04858269Trial NCT04797884Trial NCT04677816Trial NCT04659993Trial NCT04623515Trial NCT04586127Trial NCT04526080Trial NCT04495751Trial NCT04485026Trial NCT04454489Trial NCT04430335Trial NCT04415944Trial NCT04375384Trial NCT04337580Trial NCT04327700Trial NCT04266470Trial NCT04253964Trial NCT04217317Trial NCT04174742Trial NCT04173247Trial NCT04111107Trial NCT04040244Trial NCT04037527Trial NCT03998189Trial NCT03987568Trial NCT03987555Trial NCT03982537Trial NCT03963739Trial NCT03958747Trial NCT03929211Trial NCT03890614Trial NCT03880526Trial NCT03874065Trial NCT03870529Trial NCT03870451Trial NCT03868943Trial NCT03867175Trial NCT03861091Trial NCT03861065Trial NCT03796273Trial NCT03746262Trial NCT03741868Trial NCT03741829Trial NCT03740035Trial NCT03681405Trial NCT03662074Trial NCT03529565Trial NCT03520283Trial NCT03505762Trial NCT03505736Trial NCT03505671Trial NCT03379376Trial NCT03374995Trial NCT03370159Trial NCT03188432Trial NCT03152786Trial NCT03148080Trial NCT03139435Trial NCT03122743Trial NCT03087591Trial NCT03032250Trial NCT02971410Trial NCT02971397Trial NCT02949843Trial NCT02835222Trial NCT02835066Trial NCT02832154Trial NCT02827838Trial NCT02747407

Abstract

The Biomolecular Resource Laboratory (BRL) is a heavily used core service laboratory of the Comprehensive Cancer Center that supported the research laboratory activities of 41 Cancer Center members during fiscal year 2005. The BRL provides strategically important analytical services to Center members for 1) characterization of DMA, peptides, proteins and 2) identification and quantification of lipids, proteins, and peptides. These services include five different types of mass spectrometry for analysis of proteins, peptides and lipids, automated DNA sequence analysis, synthesis of RNA and DNA oligonucleotides, purification of peptides and proteins, and chemical synthesis of peptides. The BRL analyzed more than 14,000 samples during the reporting period. DNA sequence analysis (7924 samples) and mass spectrometry (6403 samples) were the most heavily used core services in the BRL. The protein/peptide and DNA chemical services accounted for an additional 956 samples. Laboratories of Cancer Center members received 49% of the services performed in the BRL during fiscal year 2005. The BRL has expanded significantly since the last review. Mass spectrometry services have been added to meet the significant needs of Cancer Center members for metabolomics and proteomics. During the last funding period, three new mass spectrometers were added to the facility. These included two Bruker mass spectrometers (an Autoflex MALDI-TOF and an Esquire HCT ion trap) and a Waters/Micromass Quadrupole Time-of-flight (Q-TOF) mass spectrometer, specifically to enhance the study of proteins and lipids. Dr. Michael Thomas, a leading expert in the analysis of lipids and lipid metabolites by mass spectrometry, has joined the laboratory as a co-director with Dr. Mark Lively. The addition of Dr. Thomas, and his staff and instrumentation, has enhanced the ability of the BRL to meet the needs of the Cancer Center program members in the especially important areas of proteomics and metabolomics. Together, Drs. Lively and Thomas provide significant expertise in biochemistry of proteins and DNA, mass spectrometry, and analytical methods to enhance and promote cancer research in the CCCWFU.

View original record on NIH RePORTER →